← Human Trials & Peer-Reviewed Studies
A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain.
Plain-language guide to PMID 12566175 (2003): double-blind randomized controlled trial of Cholecystokinin (CCK) in 40 subjects, chronic pain: fibromyalgia & crps.
Key Facts
- PMID
- 12566175
- Journal
- Neuroscience letters
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- McCleane GJ
- DOI
- 10.1016/s0304-3940(02)01388-5
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Cholecystokinin (CCK) in the context of chronic pain: fibromyalgia & crps.
The aim of this study was to establish if the cholecystokinin (CCK) 2 antagonist L-365,260 augments the analgesic effect of morphine in human subjects with chronic neuropathic pain.
Why It Was Studied
This is a randomised, double blind, placebo controlled study of 40 adult subjects taking morphine for neuropathic pain.
Pain, activity, sedation, sleep and side effects were recorded along with 12 lead ECGs, renal and liver function tests and full blood pictures.
Who Took Part
According to the abstract, 40 subjects were involved.
PubMed indexes the participants as middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.
Because people in this Cholecystokinin (CCK) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the subjects and researchers unaware of who received Cholecystokinin (CCK).
Some subjects received a placebo instead of Cholecystokinin (CCK), giving a reference point.
Each person switched between Cholecystokinin (CCK) and the comparison at some point, usually with a gap in between.
What Was Measured
Pain, activity, sedation, sleep and side effects were recorded along with 12 lead ECGs, renal and liver function tests and full blood pictures.
PubMed files the paper under topics including Analgesics, Opioid, Benzodiazepinones, Chronic Disease, Intractable Pain, Peripheral Nervous System Diseases, Phenylurea Compounds and Receptor, Cholecystokinin B.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Cholecystokinin (CCK) in 40 subjects in people with chronic pain: fibromyalgia & crps.
The publication is from 2003 (Neuroscience letters), a journal based in Ireland.
More context: the Cholecystokinin (CCK) compound page, Chronic pain: fibromyalgia & CRPS research.
Our Notes on the Compound
Cholecystokinin (CCK): A gut and brain peptide hormone that stimulates gallbladder contraction and signals fullness.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.